Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats

Directly testing proposed clinical dosing regimens in nonclinical studies can reduce the risk during the development of novel antibacterial agents. Optimal dosing regimens can be identified in animal models by testing recreated human pharmacokinetic profiles. An example of this approach using contin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoover, Jennifer L., Singley, Christine M., Elefante, Philippa, DeMarsh, Peter, Zalacain, Magdalena, Rittenhouse, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655044/
https://www.ncbi.nlm.nih.gov/pubmed/28807913
http://dx.doi.org/10.1128/AAC.00959-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655044/
https://www.ncbi.nlm.nih.gov/pubmed/28807913
http://dx.doi.org/10.1128/AAC.00959-17

Ejemplares similares